In one study, DJBL placement in patients with obesity and type 2 diabetes led to early and sustained improvements in MASLD-related plasma markers: at 3 months, AST fell by 7 IU/L, ALT by 22 IU/L, and γ-GT by 22 IU/L (all p < 0.05). The gene discussed is GPT; the disease is Obesity.